Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Noradrenergic modulation of saccades in Parkinson's disease.
Orlando IF, Hezemans FH, Ye R, Murley AG, Holland N, Regenthal R, Barker RA, Williams-Gray CH, Passamonti L, Robbins TW, Rowe JB, O'Callaghan C. Orlando IF, et al. Among authors: regenthal r. Brain Commun. 2024 Sep 1;6(5):fcae297. doi: 10.1093/braincomms/fcae297. eCollection 2024. Brain Commun. 2024. PMID: 39464213 Free PMC article.
Noradrenergic deficits contribute to apathy in Parkinson's disease through the precision of expected outcomes.
Hezemans FH, Wolpe N, O'Callaghan C, Ye R, Rua C, Jones PS, Murley AG, Holland N, Regenthal R, Tsvetanov KA, Barker RA, Williams-Gray CH, Robbins TW, Passamonti L, Rowe JB. Hezemans FH, et al. Among authors: regenthal r. PLoS Comput Biol. 2022 May 9;18(5):e1010079. doi: 10.1371/journal.pcbi.1010079. eCollection 2022 May. PLoS Comput Biol. 2022. PMID: 35533200 Free PMC article. Clinical Trial.
Improving response inhibition in Parkinson's disease with atomoxetine.
Ye Z, Altena E, Nombela C, Housden CR, Maxwell H, Rittman T, Huddleston C, Rae CL, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Ye Z, et al. Among authors: regenthal r. Biol Psychiatry. 2015 Apr 15;77(8):740-8. doi: 10.1016/j.biopsych.2014.01.024. Epub 2014 Feb 7. Biol Psychiatry. 2015. PMID: 24655598 Free PMC article. Clinical Trial.
Targeting impulsivity in Parkinson's disease using atomoxetine.
Kehagia AA, Housden CR, Regenthal R, Barker RA, Müller U, Rowe J, Sahakian BJ, Robbins TW. Kehagia AA, et al. Among authors: regenthal r. Brain. 2014 Jul;137(Pt 7):1986-97. doi: 10.1093/brain/awu117. Epub 2014 Jun 3. Brain. 2014. PMID: 24893708 Free PMC article. Clinical Trial.
Predicting beneficial effects of atomoxetine and citalopram on response inhibition in Parkinson's disease with clinical and neuroimaging measures.
Ye Z, Rae CL, Nombela C, Ham T, Rittman T, Jones PS, Rodríguez PV, Coyle-Gilchrist I, Regenthal R, Altena E, Housden CR, Maxwell H, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Ye Z, et al. Among authors: regenthal r. Hum Brain Mapp. 2016 Mar;37(3):1026-37. doi: 10.1002/hbm.23087. Epub 2016 Jan 12. Hum Brain Mapp. 2016. PMID: 26757216 Free PMC article. Clinical Trial.
Atomoxetine restores the response inhibition network in Parkinson's disease.
Rae CL, Nombela C, Rodríguez PV, Ye Z, Hughes LE, Jones PS, Ham T, Rittman T, Coyle-Gilchrist I, Regenthal R, Sahakian BJ, Barker RA, Robbins TW, Rowe JB. Rae CL, et al. Among authors: regenthal r. Brain. 2016 Aug;139(Pt 8):2235-48. doi: 10.1093/brain/aww138. Epub 2016 Jun 24. Brain. 2016. PMID: 27343257 Free PMC article. Clinical Trial.
Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans.
Skandali N, Rowe JB, Voon V, Deakin JB, Cardinal RN, Cormack F, Passamonti L, Bevan-Jones WR, Regenthal R, Chamberlain SR, Robbins TW, Sahakian BJ. Skandali N, et al. Among authors: regenthal r. Neuropsychopharmacology. 2018 Dec;43(13):2645-2651. doi: 10.1038/s41386-018-0229-z. Epub 2018 Sep 26. Neuropsychopharmacology. 2018. PMID: 30305705 Free PMC article.
88 results